moxonidine has been researched along with Chronic Disease in 3 studies
moxonidine: structure given in first source
Chronic Disease: Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).
| Excerpt | Relevance | Reference |
|---|---|---|
| "A total of 268 patients with chronic heart failure in NYHA functional class II to IV on optimal standard therapy were randomized to placebo or 1 of 5 doses of moxonidine SR: 0." | 9.10 | Effects of sustained-release moxonidine, an imidazoline agonist, on plasma norepinephrine in patients with chronic heart failure. ( Bristow, MR; Cohn, JN; Dargie, H; Straub, M; Swedberg, K; Wiltse, C; Wright, TJ, 2002) |
| "A total of 268 patients with chronic heart failure in NYHA functional class II to IV on optimal standard therapy were randomized to placebo or 1 of 5 doses of moxonidine SR: 0." | 5.10 | Effects of sustained-release moxonidine, an imidazoline agonist, on plasma norepinephrine in patients with chronic heart failure. ( Bristow, MR; Cohn, JN; Dargie, H; Straub, M; Swedberg, K; Wiltse, C; Wright, TJ, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lechin, F | 1 |
| Lechin, M | 1 |
| van der Dijs, B | 1 |
| Coats, AJ | 1 |
| Swedberg, K | 1 |
| Bristow, MR | 1 |
| Cohn, JN | 1 |
| Dargie, H | 1 |
| Straub, M | 1 |
| Wiltse, C | 1 |
| Wright, TJ | 1 |
2 trials available for moxonidine and Chronic Disease
| Article | Year |
|---|---|
Heart Failure 99 -- the MOXCON story.
Topics: Adverse Drug Reaction Reporting Systems; Antihypertensive Agents; Chronic Disease; Dose-Response Rel | 1999 |
Effects of sustained-release moxonidine, an imidazoline agonist, on plasma norepinephrine in patients with chronic heart failure.
Topics: Blood Pressure; Chronic Disease; Delayed-Action Preparations; Dose-Response Relationship, Drug; Doub | 2002 |
1 other study available for moxonidine and Chronic Disease
| Article | Year |
|---|---|
Plasma catecholamines and chronic congestive heart failure.
Topics: Adrenal Glands; Catecholamines; Chronic Disease; Clonidine; Diagnostic Techniques, Cardiovascular; D | 2002 |